Yoshiko Okita1, Yoshitaka Narita2, Ruriko Miyahara3, Yasuji Miyakita3, Makoto Ohno3, Soichiro Shibui4. 1. Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo Department of Neurosurgery, Osaka National Hospital, National Hospital Organization, Osaka. 2. Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo yonarita@ncc.go.jp. 3. Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo. 4. Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo Department of Neurosurgery, Teikyo University School of Medicine University Hospital, Mizonokuchi, Kawasaki, Kanagawa, Japan.
Abstract
OBJECTIVE: Although the number of long-term survivors of glioma has increased, there has been little research on the health-related quality of life of long-term survivors of Grade II glioma following treatment with surgery, radiotherapy and chemotherapy. In this study, we aimed to document the health-related quality of life of people diagnosed with Grade II glioma who had survived >10 years with no evidence of disease at the time of the health-related quality of life survey. METHODS: To investigate the health-related quality of life of Grade II glioma survivors without evidence of disease, we surveyed 50 patients 0-20 years after their initial treatments. Each patient completed a multi-part health-related quality of life questionnaire. Based on these surveys, we examined the relationships between health-related quality of life scores and time since initial treatment, Karnofsky Performance Scale scores at the time of the survey, and history of recurrence, radiotherapy and chemotherapy. RESULTS: Excepting bladder control, long-term survivors maintained their quality of life as determined by comparing patients surveyed < 5 and ≥ 10 years after their initial treatment (P < 0.05). Neither radiotherapy nor chemotherapy at the initial treatment was observed to affect health-related quality of life. However, a history of recurrence was significantly associated with deteriorations in many health-related quality of life functional and symptom scores. The Karnofsky Performance Scale scores of patients with a history of recurrence were significantly lower than those without it (P = 0.02). This deterioration was observed in both univariate and multivariate analyses. CONCLUSIONS: Our results indicate that declines in health-related quality of life among long-term survivors of Grade II glioma mainly result from impaired Karnofsky Performance Scale, which is a consequence of disease recurrence.
OBJECTIVE: Although the number of long-term survivors of glioma has increased, there has been little research on the health-related quality of life of long-term survivors of Grade II glioma following treatment with surgery, radiotherapy and chemotherapy. In this study, we aimed to document the health-related quality of life of people diagnosed with Grade II glioma who had survived >10 years with no evidence of disease at the time of the health-related quality of life survey. METHODS: To investigate the health-related quality of life of Grade II glioma survivors without evidence of disease, we surveyed 50 patients 0-20 years after their initial treatments. Each patient completed a multi-part health-related quality of life questionnaire. Based on these surveys, we examined the relationships between health-related quality of life scores and time since initial treatment, Karnofsky Performance Scale scores at the time of the survey, and history of recurrence, radiotherapy and chemotherapy. RESULTS: Excepting bladder control, long-term survivors maintained their quality of life as determined by comparing patients surveyed < 5 and ≥ 10 years after their initial treatment (P < 0.05). Neither radiotherapy nor chemotherapy at the initial treatment was observed to affect health-related quality of life. However, a history of recurrence was significantly associated with deteriorations in many health-related quality of life functional and symptom scores. The Karnofsky Performance Scale scores of patients with a history of recurrence were significantly lower than those without it (P = 0.02). This deterioration was observed in both univariate and multivariate analyses. CONCLUSIONS: Our results indicate that declines in health-related quality of life among long-term survivors of Grade II glioma mainly result from impaired Karnofsky Performance Scale, which is a consequence of disease recurrence.
Authors: Ben Rimmer; Iakov Bolnykh; Lizzie Dutton; Joanne Lewis; Richéal Burns; Pamela Gallagher; Sophie Williams; Vera Araújo-Soares; Fiona Menger; Linda Sharp Journal: Qual Life Res Date: 2022-08-06 Impact factor: 3.440
Authors: Sé Maria Frances; Galina Velikova; Martin Klein; Susan C Short; Louise Murray; Judy M Wright; Florien Boele Journal: Neurooncol Pract Date: 2021-11-10